Your browser doesn't support javascript.
loading
SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation.
Palomer, Xavier; Román-Azcona, M Silvia; Pizarro-Delgado, Javier; Planavila, Ana; Villarroya, Francesc; Valenzuela-Alcaraz, Brenda; Crispi, Fátima; Sepúlveda-Martínez, Álvaro; Miguel-Escalada, Irene; Ferrer, Jorge; Nistal, J Francisco; García, Raquel; Davidson, Mercy M; Barroso, Emma; Vázquez-Carrera, Manuel.
Afiliação
  • Palomer X; Department of Pharmacology, Toxicology and Therapeutic Chemistry, IBUB (Institut de Biomedicina de la Universitat de Barcelona), Research Institute - Pediatric Research Institute, Hospital Sant Joan de Déu, and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Faculty of Pharmacy an
  • Román-Azcona MS; Department of Pharmacology, Toxicology and Therapeutic Chemistry, IBUB (Institut de Biomedicina de la Universitat de Barcelona), Research Institute - Pediatric Research Institute, Hospital Sant Joan de Déu, and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Faculty of Pharmacy an
  • Pizarro-Delgado J; Department of Pharmacology, Toxicology and Therapeutic Chemistry, IBUB (Institut de Biomedicina de la Universitat de Barcelona), Research Institute - Pediatric Research Institute, Hospital Sant Joan de Déu, and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Faculty of Pharmacy an
  • Planavila A; Department of Biochemistry and Molecular Biomedicine, IBUB and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Faculty of Biology, University of Barcelona, Barcelona, Spain.
  • Villarroya F; Department of Biochemistry and Molecular Biomedicine, IBUB and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Faculty of Biology, University of Barcelona, Barcelona, Spain.
  • Valenzuela-Alcaraz B; aBCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, and Center for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain.
  • Crispi F; aBCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, and Center for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain.
  • Sepúlveda-Martínez Á; aBCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, and Center for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain.
  • Miguel-Escalada I; Genomic Programming of Beta-cells Laboratory, Institut d'Investigacions August Pi i Sunyer (IDIBAPS), and CIBERDEM, Barcelona, Spain.
  • Ferrer J; Genomic Programming of Beta-cells Laboratory, Institut d'Investigacions August Pi i Sunyer (IDIBAPS), and CIBERDEM, Barcelona, Spain.
  • Nistal JF; Section of Epigenomics and Disease, Department of Medicine, and National Institute for Health Research (NIHR) Imperial Biomedical Research Centre, Imperial College London, London, UK.
  • García R; Servicio de Cirugía Cardiovascular, Hospital Universitario Marqués de Valdecilla, Departamento de Ciencias Médicas y Quirúrgicas, Facultad de Medicina, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Centro de Investigación Biomédica en Red Cardiovascular (CIBERC
  • Davidson MM; Departamento de Fisiología y Farmacología, Facultad de Medicina, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
  • Barroso E; Department of Radiation Oncology, Columbia University, New York, NY, USA.
  • Vázquez-Carrera M; Department of Pharmacology, Toxicology and Therapeutic Chemistry, IBUB (Institut de Biomedicina de la Universitat de Barcelona), Research Institute - Pediatric Research Institute, Hospital Sant Joan de Déu, and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Faculty of Pharmacy an
Signal Transduct Target Ther ; 5(1): 14, 2020 02 28.
Article em En | MEDLINE | ID: mdl-32296036
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrose / Proteínas Proto-Oncogênicas c-fos / Fator de Transcrição AP-1 / Sirtuína 3 / Insuficiência Cardíaca Limite: Animals / Humans Idioma: En Revista: Signal Transduct Target Ther Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrose / Proteínas Proto-Oncogênicas c-fos / Fator de Transcrição AP-1 / Sirtuína 3 / Insuficiência Cardíaca Limite: Animals / Humans Idioma: En Revista: Signal Transduct Target Ther Ano de publicação: 2020 Tipo de documento: Article